<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Obstetrics and Gynaecology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/16B9E8DF-8684-4157-A40C-478DFD09BAA8"><gtr:id>16B9E8DF-8684-4157-A40C-478DFD09BAA8</gtr:id><gtr:firstName>Christian</gtr:firstName><gtr:otherNames>M.</gtr:otherNames><gtr:surname>Becker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0601458"><gtr:id>2A0176A7-E8E5-4A84-9196-439DD59D2BB9</gtr:id><gtr:title>Transgenic mouse model of endometriosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601458</gtr:grantReference><gtr:abstractText>Endometriosis is a common disease, which causes painful periods, pelvic pain and infertility. It is defined as the presence of endometrium (the lining of the uterus) in sites outside the uterine cavity such as the ovaries. This tissue undergoes the same transformation each month as normal endometrium inside the uterus: namely a monthly bleed which causes the above symptoms. It is estimated that about 14 million women in the European Union are affected by endometriosis. Aside from these devastating symptoms and their effect on a woman?s quality of life, endometriosis has a significant economic impact on society. For example, it has been calculated that the disease costs up to ?30 billion annually as a result of missed days at work. 
Current treatment options are unsatisfactory as they are often associated with significant side effects and recurrence of the disease. The main reason is that we know very little about the basic molecular mechanisms involved in endometriosis. Clearly, if we could only understand better what causes endometriosis, we might be able to develop better treatments.
In the proposed study, we shall for the first time create a mouse model of endometriosis which allows the development of the disease to be monitored over time without performing repeated surgery. We will breed mice with a specific gene defect (which means that they can be made to develop endometriosis spontaneously) with other genetically engineered mice that contain a protein called luciferase in their cells. This protein is used in nature by fireflies to cause luminescence. When the endometriosis causing gene is switched on in these specially bred mice, the parts of the abdomen which contain disease will appear to glow when the whole body is placed under a special camera. The intensity of the light signal seen outside the body is equal to the size of the endometriosis lesion inside the body. We will therefore be able to monitor the effect of treatment on the lesions from the outside without having to perform surgery. Consequently, we will be able to reduce significantly the number of animals that need to be used in such studies in the future. This model will help us to understand the underlying causes of endometriosis. We will be able to investigate molecular mechanisms and genes that are important during establishment and growth of endometriosis lesions and test new drugs, which hopefully will improve the quality of life of affected patients.</gtr:abstractText><gtr:technicalSummary>Endometriosis affects 10-15% of women in their reproductive years. Typical symptoms include severe dysmenorrhoea, pelvic pain and subfertility. Novel therapeutic approaches are urgently needed as current treatment options are associated with significant side effects and high recurrence rates. An adequate animal model would facilitate testing of new compounds and increase our understanding of their effect on disease processes at a molecular and cellular level.
A mouse model of ?spontaneous? disease has recently been published in which conditional upregulation of K-ras in the ovarian epithelium led to endometriotic lesions in the abdominal cavity of half the animals. However, disease development cannot be monitored in this model without performing repeated surgery. We believe the problem can be overcome using luceriferase technology, which we developed in an alternative disease model involving transplantation of transgenic endometrial tissue from luciferase expressing mice into the abdominal cavity of wild-type mice, allowing angiogenesis and lesion growth to be monitored non-invasively.
The proposed study combines the advantages of the K-ras model and luciferase technology by breeding genetically engineered K-ras mice to existing reporter mice in which luciferase is switched on by cre-mediated recombination. Thus, it will be possible for the first time to monitor the growth of spontaneous endometriotic lesions non-invasively with in vivo imaging. The effects of angiogenesis inhibitors on the development of the disease can also be studied. In addition, changes in gene and protein expression in endometriotic tissue will be detectable at various developmental stages and in response to antiangiogenic treatment. Another advantage of this model is that it will significantly reduce the number of animals needed for future studies. The findings hopefully will lead to future drug discovery, which will ultimatelly improve the situation for affected patients.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-01</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>363826</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Establishment and characterisation of K-ras transgenic mouse model of endometriosis</gtr:description><gtr:id>9D445910-6EE1-44B7-8057-5BC8002803FC</gtr:id><gtr:impact>The contract has been signed today and we are starting to breed animals now.</gtr:impact><gtr:partnerContribution>With the collaboration we will be able to characterise the model much better. We will try a different approach to activate K-ras expression and thereby endometriotic growth.</gtr:partnerContribution><gtr:piContribution>The MRC-funded mouse model is of significant interest to companies such as Bayer Schering who are interested in endometriosis. The idea, animals and technical know-how comes from me /my lab members. The work will be performed mainly in Oxford as the animals are here.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Bayer HealthCare</gtr:department><gtr:description>Oxford Bayer Collaboration on Endometriosis and Fibroids</gtr:description><gtr:id>A8E49B3A-2E59-4D00-B5C9-DC1670729B39</gtr:id><gtr:impact>Just started</gtr:impact><gtr:partnerContribution>Joint funding; research input</gtr:partnerContribution><gtr:piContribution>PI and collaborator on various projects under this umbrella; joint funding</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Obstetrics &amp; Gynaecology</gtr:department><gtr:description>Development of an endometriosis centre of expertise</gtr:description><gtr:id>3F96CC89-A79B-45F3-8CAF-F56F4BFF58A4</gtr:id><gtr:impact>None so far.</gtr:impact><gtr:partnerContribution>Restructuring of service, significant improvements in bench-to-bedside worklines.</gtr:partnerContribution><gtr:piContribution>Combining forces with clinicians and researchers to expad and improve the existing centre into a world leading institution.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>CRUK/MRC Oxford Institute for Radiation Oncology</gtr:department><gtr:description>Development of ovarian cancer</gtr:description><gtr:id>C200F0AB-487F-4719-9C4B-129875FB8993</gtr:id><gtr:impact>Publications currently being written.</gtr:impact><gtr:piContribution>We developed a novel model of ovarian cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Obstetrics &amp; Gynaecology</gtr:department><gtr:description>Investigation of platinum resistance in a mouse model of ovarian cancer</gtr:description><gtr:id>0C78C8EB-7917-4678-8A0E-B9B3D09463E5</gtr:id><gtr:impact>This project is currently underway to collect preliminary data for a subsequent grant application.</gtr:impact><gtr:partnerContribution>By combining our K-ras/Luciferase mouse model with PTEN mice we are able to detect the growth of ovarian cancer non-invasively which is one of the aims of the lab.</gtr:partnerContribution><gtr:piContribution>We provide the mice and technical skills to this project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>RCOG Guidelines in Endometriosis</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>99E6BF1D-FF5D-4282-9DED-05D9619058E7</gtr:id><gtr:impact>Guideline update for the diagnosis and treatment of endometriosis in the UK

National guideline for all healthcare professionals in the UK</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gynaecologist Meeting, Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>777A9AD1-7365-4074-819F-3CED53F726CE</gtr:id><gtr:impact>25 consultant gynaecologist attanded a series of talks. Mine was on endometriosis and on animal models.

Children of colleagues came to the department to learn more about our research as a career option.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open day for Endometriosis UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2ADC6976-6DB9-48B6-AF57-3ECC670A3FA7</gtr:id><gtr:impact>Approximately 100 patients, researchers, activists attended meeting in London, leading to long panel discussion afterwards.

Will be invited again next time.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invitation to Bayer Schering, Berlin, Germany</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F5204442-9BBE-458B-94AF-26C5B727FAC3</gtr:id><gtr:impact>A invitation by a pharma company to learn about animal models of endometriosis.

A collaboration/funding was agreed.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GROW Science Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E514CB84-909A-4A4C-AD83-4C4B8727DC06</gtr:id><gtr:impact>200 people attended this Science Day of the University of Maastricht

Keynote lecture at this prestigous conference</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.grow-um.nl/tinimce_files/Science_Day_2013_Programma.pdf</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Industry-Academic Endometriosis Focus Group Meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4FAEE287-BA30-4F25-9776-C6D35F80260E</gtr:id><gtr:impact>First meeting with different pharma companies to discuss the importance or biomarkers for endometriosis

A consortium was formed to search for biomarkers of endometriosis</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>493631</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CA32A7C0-E002-4D87-8EDB-7AEE1A4ED126</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>205000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Bayer HealthCare</gtr:department><gtr:description>Collaborative Research Grant</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Bayer</gtr:fundingOrg><gtr:id>4DDB948D-2CFD-47AD-BD0A-9309BCA22BD4</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Bayer HealthCare</gtr:department><gtr:description>Reseach Grant</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Bayer</gtr:fundingOrg><gtr:id>907F395B-799D-4A2F-ACB3-ACD733427C0A</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Reserch Fund</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Trust</gtr:fundingOrg><gtr:id>DDC49E29-B94B-450C-8196-800A59FE48FD</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>363823</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>Senior Research Fellowship</gtr:description><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>957D5199-C27C-43EE-9454-5A462493581F</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ESHRE Guidelines for Endometriosis</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>916CADA6-772A-496F-B792-03D51FC809B0</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>RCOG Endometriosis Guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>3D97C39B-0800-41AE-8157-49857FC029C5</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Bioluminescent ovarian cancer cell line can be used for multiple applications. Manuscript.</gtr:description><gtr:id>1C0C3491-9329-4FAA-966D-50D0FE25F2FB</gtr:id><gtr:impact>Currently ongoing studies.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Ovarian cancer cell line</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The mouse model helps to detect and follow growth ad possibly therapeutic efficacy of endometriosis lesions non-invasively.</gtr:description><gtr:id>8E30C7E2-0B39-4701-A3B5-2891EB888794</gtr:id><gtr:impact>This first genetic, non-nvasive mouse model of endometriosis will be highly attractive for testing drugs and investigate the pathogenesis of the disease. As a result we have started a collaboration with a pharma company already.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Non-invasive mouse model of endometriosis</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A novel model of spontaneous ovarian cancer has been developed which can be used for genetic modifications, monitoring and treatment.</gtr:description><gtr:id>B55BB8EA-E964-4AB7-B73C-A4E545F3F844</gtr:id><gtr:impact>Currently ongoing studies. Manuscript.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Non-invasive mouse model of ovarian cancer</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Geneticlly modified mice.</gtr:description><gtr:id>CE3AFBFF-9852-41E0-A55A-2CF992580BF7</gtr:id><gtr:impact>None.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mouse model of uterine fibroids</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F3C2EE70-62FA-43B9-BC5A-1AA1ACA83BD2"><gtr:id>F3C2EE70-62FA-43B9-BC5A-1AA1ACA83BD2</gtr:id><gtr:title>Consensus on current management of endometriosis.</gtr:title><gtr:parentPublicationTitle>Human reproduction (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/85d25a48b48c5f7abaab51f454e9215d"><gtr:id>85d25a48b48c5f7abaab51f454e9215d</gtr:id><gtr:otherNames>Johnson NP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0268-1161</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/441A0350-7DE6-4E3A-93BD-2387502D4F8E"><gtr:id>441A0350-7DE6-4E3A-93BD-2387502D4F8E</gtr:id><gtr:title>Central changes associated with chronic pelvic pain and endometriosis.</gtr:title><gtr:parentPublicationTitle>Human reproduction update</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f2022bd356f4bc6c07a8920618cd7b07"><gtr:id>f2022bd356f4bc6c07a8920618cd7b07</gtr:id><gtr:otherNames>Brawn J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1355-4786</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/158822A4-DBBF-46EA-9CD8-6A8BF13E1C87"><gtr:id>158822A4-DBBF-46EA-9CD8-6A8BF13E1C87</gtr:id><gtr:title>2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dff2767a747358fc7ec9bf49d8538079"><gtr:id>dff2767a747358fc7ec9bf49d8538079</gtr:id><gtr:otherNames>Becker CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4CF2453B-A8AC-4223-A42D-1B258876AA3D"><gtr:id>4CF2453B-A8AC-4223-A42D-1B258876AA3D</gtr:id><gtr:title>World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: IV. Tissue collection, processing, and storage in endometriosis research.</gtr:title><gtr:parentPublicationTitle>Fertility and sterility</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8a72d8c6ed34487f0ffe8ad70be3845b"><gtr:id>8a72d8c6ed34487f0ffe8ad70be3845b</gtr:id><gtr:otherNames>Fassbender A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0015-0282</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/33A76993-B0F2-4C8C-BBE9-6C7AF3B9D437"><gtr:id>33A76993-B0F2-4C8C-BBE9-6C7AF3B9D437</gtr:id><gtr:title>Targeting tyrosine-kinases in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Expert opinion on investigational drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7834f04b6fce9a2cf050fd961a3d5a0f"><gtr:id>7834f04b6fce9a2cf050fd961a3d5a0f</gtr:id><gtr:otherNames>Morotti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1354-3784</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/57D58157-1F0C-4DEC-849F-837F369F9F3E"><gtr:id>57D58157-1F0C-4DEC-849F-837F369F9F3E</gtr:id><gtr:title>Peripheral changes in endometriosis-associated pain.</gtr:title><gtr:parentPublicationTitle>Human reproduction update</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7834f04b6fce9a2cf050fd961a3d5a0f"><gtr:id>7834f04b6fce9a2cf050fd961a3d5a0f</gtr:id><gtr:otherNames>Morotti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1355-4786</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BED992FE-5F0C-4530-8587-F2027C4EA792"><gtr:id>BED992FE-5F0C-4530-8587-F2027C4EA792</gtr:id><gtr:title>Urinary peptide profiling identifies a panel of putative biomarkers for diagnosing and staging endometriosis.</gtr:title><gtr:parentPublicationTitle>Fertility and sterility</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b119451075adcd080b895390c4d82b7c"><gtr:id>b119451075adcd080b895390c4d82b7c</gtr:id><gtr:otherNames>El-Kasti MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0015-0282</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/51463EBD-3D21-4F78-864F-44A57954B3F6"><gtr:id>51463EBD-3D21-4F78-864F-44A57954B3F6</gtr:id><gtr:title>World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research.</gtr:title><gtr:parentPublicationTitle>Fertility and sterility</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/840bea2744072e0dab13f36c746d647c"><gtr:id>840bea2744072e0dab13f36c746d647c</gtr:id><gtr:otherNames>Rahmioglu N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0015-0282</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B253FD2A-576C-4ECB-80FD-2CAFE6C4E302"><gtr:id>B253FD2A-576C-4ECB-80FD-2CAFE6C4E302</gtr:id><gtr:title>Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dff2767a747358fc7ec9bf49d8538079"><gtr:id>dff2767a747358fc7ec9bf49d8538079</gtr:id><gtr:otherNames>Becker CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6B715332-08AE-4795-8768-97D1C52E42E2"><gtr:id>6B715332-08AE-4795-8768-97D1C52E42E2</gtr:id><gtr:title>Do we know what causes endometriosis?</gtr:title><gtr:parentPublicationTitle>British journal of hospital medicine (London, England : 2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c87ba11d7d5b0bf6123c67fb81ae065f"><gtr:id>c87ba11d7d5b0bf6123c67fb81ae065f</gtr:id><gtr:otherNames>Wagstaff D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1750-8460</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/75B33B83-3AEE-4C9A-9691-A7D96EB38AEA"><gtr:id>75B33B83-3AEE-4C9A-9691-A7D96EB38AEA</gtr:id><gtr:title>Levels of circulating angiogenic cells are not altered in women with endometriosis.</gtr:title><gtr:parentPublicationTitle>Human reproduction (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c3c6a7a53efeb9e864a1c6de8022e8e"><gtr:id>4c3c6a7a53efeb9e864a1c6de8022e8e</gtr:id><gtr:otherNames>Webster KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0268-1161</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FE6EB882-49B4-44DF-AF36-53B8D1E1764D"><gtr:id>FE6EB882-49B4-44DF-AF36-53B8D1E1764D</gtr:id><gtr:title>Matrix metalloproteinases are elevated in the urine of patients with endometriosis.</gtr:title><gtr:parentPublicationTitle>Fertility and sterility</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dff2767a747358fc7ec9bf49d8538079"><gtr:id>dff2767a747358fc7ec9bf49d8538079</gtr:id><gtr:otherNames>Becker CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0015-0282</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DBBDD362-54B4-4767-95F6-9E1F31429FB6"><gtr:id>DBBDD362-54B4-4767-95F6-9E1F31429FB6</gtr:id><gtr:title>Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c34a45830a7d60cd656076d911cff8d3"><gtr:id>c34a45830a7d60cd656076d911cff8d3</gtr:id><gtr:otherNames>Pakneshan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A83FE9A8-98A6-4649-BB9E-7965B99EE678"><gtr:id>A83FE9A8-98A6-4649-BB9E-7965B99EE678</gtr:id><gtr:title>Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo.</gtr:title><gtr:parentPublicationTitle>Fertility and sterility</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/278fcc443baec484a682f08515697559"><gtr:id>278fcc443baec484a682f08515697559</gtr:id><gtr:otherNames>Xu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0015-0282</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5A43B600-6789-4954-8D70-CC8485B625D3"><gtr:id>5A43B600-6789-4954-8D70-CC8485B625D3</gtr:id><gtr:title>ESHRE guideline: management of women with endometriosis.</gtr:title><gtr:parentPublicationTitle>Human reproduction (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7763f816194c109565562dc6a4bf6ccb"><gtr:id>7763f816194c109565562dc6a4bf6ccb</gtr:id><gtr:otherNames>Dunselman GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0268-1161</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C51A3923-F9AE-44DB-B2DC-1B652AEEE386"><gtr:id>C51A3923-F9AE-44DB-B2DC-1B652AEEE386</gtr:id><gtr:title>World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: II. Clinical and covariate phenotype data collection in endometriosis research.</gtr:title><gtr:parentPublicationTitle>Fertility and sterility</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9dc68e157c6d98ffb3209478ec674b9d"><gtr:id>9dc68e157c6d98ffb3209478ec674b9d</gtr:id><gtr:otherNames>Vitonis AF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0015-0282</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/36F070B6-A9A7-47ED-8639-6918B5CE8C5A"><gtr:id>36F070B6-A9A7-47ED-8639-6918B5CE8C5A</gtr:id><gtr:title>Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis.</gtr:title><gtr:parentPublicationTitle>Angiogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/278fcc443baec484a682f08515697559"><gtr:id>278fcc443baec484a682f08515697559</gtr:id><gtr:otherNames>Xu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-6970</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD6B35B1-9FD7-40EE-95AD-CBE3F45DE430"><gtr:id>AD6B35B1-9FD7-40EE-95AD-CBE3F45DE430</gtr:id><gtr:title>Peripheral biomarkers of endometriosis: a systematic review.</gtr:title><gtr:parentPublicationTitle>Human reproduction update</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6001f5a8165d0d68d8c4befc42c40679"><gtr:id>6001f5a8165d0d68d8c4befc42c40679</gtr:id><gtr:otherNames>May KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1355-4786</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0BCAA1B1-DB32-4A63-BD64-90E0179A0583"><gtr:id>0BCAA1B1-DB32-4A63-BD64-90E0179A0583</gtr:id><gtr:title>Endometrial alterations in endometriosis: a systematic review of putative biomarkers.</gtr:title><gtr:parentPublicationTitle>Human reproduction update</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6001f5a8165d0d68d8c4befc42c40679"><gtr:id>6001f5a8165d0d68d8c4befc42c40679</gtr:id><gtr:otherNames>May KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1355-4786</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2C7B6BFB-1F55-48F1-9336-CDC95B055F25"><gtr:id>2C7B6BFB-1F55-48F1-9336-CDC95B055F25</gtr:id><gtr:title>The origin of ovarian cancer.</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/26fa9474fc9dc6146887ae60ec41d25a"><gtr:id>26fa9474fc9dc6146887ae60ec41d25a</gtr:id><gtr:otherNames>Ahmed AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/971682BB-10E1-4469-AC8A-0F76C19474F8"><gtr:id>971682BB-10E1-4469-AC8A-0F76C19474F8</gtr:id><gtr:title>Endometriosis and angiogenesis.</gtr:title><gtr:parentPublicationTitle>Minerva ginecologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fcbca2f8c5799fc2f16844af4b21ce43"><gtr:id>fcbca2f8c5799fc2f16844af4b21ce43</gtr:id><gtr:otherNames>May K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0026-4784</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/34BF42A1-9CEC-4F57-BD80-3CD392C4C824"><gtr:id>34BF42A1-9CEC-4F57-BD80-3CD392C4C824</gtr:id><gtr:title>World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: I. Surgical phenotype data collection in endometriosis research.</gtr:title><gtr:parentPublicationTitle>Fertility and sterility</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dff2767a747358fc7ec9bf49d8538079"><gtr:id>dff2767a747358fc7ec9bf49d8538079</gtr:id><gtr:otherNames>Becker CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0015-0282</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/63552249-8A0E-4409-A453-835F436DB295"><gtr:id>63552249-8A0E-4409-A453-835F436DB295</gtr:id><gtr:title>Potential mechanisms of postmenopausal endometriosis.</gtr:title><gtr:parentPublicationTitle>Maturitas</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2b9ed4996b59b2cef81eb4e6a796315f"><gtr:id>2b9ed4996b59b2cef81eb4e6a796315f</gtr:id><gtr:otherNames>Bendon CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0378-5122</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601458</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>